alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<PAGE>

                                                                  Exhibit 10.24B

[LOGO OF GREYROCK CAPITAL]

                           Amendment to Loan Documents

Borrowers:    Seer Technologies, Inc. and Level 8 Systems, Inc.

Address:      8000 Regency Parkway
              Cary, North Carolina  27511

Date:         March 9, 2000

     THIS AMENDMENT TO LOAN DOCUMENTS is entered into between GREYROCK CAPITAL,
a Division of Banc of America Commercial Finance Corporation ("Greyrock"), whose
address is 10880 Wilshire Blvd., Suite 1850, Los Angeles, CA 90024 and the
borrower named above ("Borrower").

     The Parties agree to amend the Loan and Security Agreement between them,
dated March 31, 1999 (as amended from time to time, the "Loan Agreement"), as
follows, effective on the date hereof. (Capitalized terms used but not defined
in this Amendment, shall have the meanings set forth in the Loan Agreement.)

     1. Replacement Term Loan Due Date. Section 1(c)(1) of the Schedule, which
currently reads as follows:

     "(1) The Replacement Term Loan shall be due and payable, in full, on the
     earlier of (A) March 1, 2001, or (B) any termination of this Agreement",

     is hereby amended in its entirety to read as follows:

     "(1) The Replacement Term Loan shall be due and payable, in full, on the
     earlier of (A) December 31, 2001, (B) the Receivable Loan Maturity Date
     (defined below), or (C) any termination of this Agreement".

     2. Representations True. Borrower represents and warrants to Greyrock that
all representations and warranties set forth in the Loan Agreement, as amended
hereby, are true and correct.

     3. General Provisions. This Amendment, the Loan Agreement, and the other
Loan Documents set forth in full all of the representations and agreements of
the parties with respect to the subject matter hereof and supersede all prior
discussions, representations, agreements and understandings between the parties
with respect to the subject hereof. Except as herein expressly amended, all

                                       1
<PAGE>

of the terms and provisions of the Loan Agreement and the other Loan Documents
shall continue in full force and effect and the same are hereby ratified and
confirmed.


Borrower:                                       Borrower:

Seer Technologies, Inc.                         LEVEL 8 SYSTEMS, INC.

By /s/ Steven Dmiszewicki                       By /s/ Steven Dmiszewicki
  ----------------------------                     ----------------------------
  President or Vice President                      President or Vice President

By /s/ Dennis McKinnie                          By /s/ Dennis McKinnie
  ----------------------------                     ----------------------------
  Secretary or Ass't Secretary                     Secretary or Ass't Secretary


Greyrock:

Greyrock Capital,
a Division of Banc of America Commercial
Finance Corporation

By     /s/  Lisa Nagano
  ----------------------------
Title  Sr. Vice President
     -------------------------

                                       2
<TABLE> <S> <C>

<ARTICLE>     9
<LEGEND>
                This schedule contains summary financial information extracted
                from the consolidated balance sheet as of September 30, 1996
                and consolidated statement of income for the nine months ended
                September 30, 1996 in the Company's September 30, 1996 Form
                10-Q and is qualified in its entirety by reference to such
                financial statements.

</LEGEND>
<MULTIPLIER>                         1,000
       
<S>                                  <C>
<PERIOD-TYPE>                        9-MOS
<FISCAL-YEAR-END>                    DEC-31-1996
<PERIOD-START>                       JAN-01-1996
<PERIOD-END>                         SEP-30-1996
<CASH>                               $    30,069
<INT-BEARING-DEPOSITS>                       542
<FED-FUNDS-SOLD>                           6,000
<TRADING-ASSETS>                               0
<INVESTMENTS-HELD-FOR-SALE>              272,493
<INVESTMENTS-CARRYING>                         0
<INVESTMENTS-MARKET>                           0
<LOANS>                                1,033,249
<ALLOWANCE>                                4,651
<TOTAL-ASSETS>                         1,445,300
<DEPOSITS>                               969,033
<SHORT-TERM>                             248,839
<LIABILITIES-OTHER>                       58,642
<LONG-TERM>                               49,317
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                  78,348
<OTHER-SE>                                41,111
<TOTAL-LIABILITIES-AND-EQUITY>         1,445,300
<INTEREST-LOAN>                           59,234
<INTEREST-INVEST>                         14,496
<INTEREST-OTHER>                             356
<INTEREST-TOTAL>                          73,986
<INTEREST-DEPOSIT>                        31,051
<INTEREST-EXPENSE>                        47,059
<INTEREST-INCOME-NET>                     26,927
<LOAN-LOSSES>                                210
<SECURITIES-GAINS>                           742
<EXPENSE-OTHER>                           77,260
<INCOME-PRETAX>                           16,571
<INCOME-PRE-EXTRAORDINARY>                10,915
<EXTRAORDINARY>                            (388)
<CHANGES>                                      0
<NET-INCOME>                              10,527
<EPS-PRIMARY>                               0.64
<EPS-DILUTED>                               0.64
<YIELD-ACTUAL>                              2.83
<LOANS-NON>                                4,591
<LOANS-PAST>                                 445
<LOANS-TROUBLED>                               0
<LOANS-PROBLEM>                                0
<ALLOWANCE-OPEN>                           5,002
<CHARGE-OFFS>                                643
<RECOVERIES>                                  92
<ALLOWANCE-CLOSE>                          4,651
<ALLOWANCE-DOMESTIC>                       3,939
<ALLOWANCE-FOREIGN>                            0
<ALLOWANCE-UNALLOCATED>                      712
        

</TABLE>
[No. 20192-5-II.

Division Two.

October 31, 1997.]

#### Kelly’s Enterprises, Inc., *Appellant,*v. Kevin Varness, et al., *Respondents.*

Appeal from a judgment of the Superior Court for Grays Harbor County, No. 93-2-00304-6, F. Mark McCauley, J., entered November 20, 1995. *Affirmed*by unpublished opinion per Bridgewater, A.C.J., concurred in by Morgan and Armstrong, JJ.
§ 310.542 Over-the-counter (OTC) drug products containing active ingredients offered for use in the treatment of hyperphosphatemia. ( a ) Hyperphosphatemia is a condition in which an abnormally high plasma level of phosphate occurs in the blood. This condition in not amenable to self-diagnosis or self-treatment. Treatment of this condition should be restricted to the supervision of a physician. For this reason, any drug product containing ingredients offered for OTC use in the treatment of hyperphosphatemia cannot be considered generally recognized as safe and effective.
( b ) Any drug product that is labeled, represented, or promoted for OTC use in the treatment of hyperphosphatemia is regarded as a new drug within the meaning of section 201(p) of the Federal Food, Drug, and Cosmetic Act (the act), for which an approved application under section 505 of the act and part 314 of this chapter is required for marketing. In the absence of an approved application, such product is also misbranded under section 502 of the act.
( c ) Clinical investigations designed to obtain evidence that any drug product labeled, represented, or promoted for use in the treatment of hyperphosphatemia is safe and effective for the purpose intended must comply with the requirements and procedures governing use of investigational new drugs set forth in part 312 of this chapter.
( d ) After November 12, 1990, any such OTC drug product initially introduced or initially delivered for introduction into interstate commerce that is not in compliance with this section is subject to regulatory action.
[55 FR 19858, May 11, 1990]
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1695 Riboflavin. ( a ) Riboflavin (C17H20N4O6, CAS Reg. No. 83-88-5) occurs as yellow to orange-yellow needles that are crystallized from 2*N* acetic acid, alcohol, water, or pyridine. It may be prepared by chemical synthesis, biosynthetically by the organism *Eremothecium ashbyii,* or isolated from natural sources.
( b ) The ingredient meets the specifications of the Food Chemicals Codex, 3d Ed. (1981), p. 262, which is incorporated by reference. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as a nutrient supplement as defined in § 170.3(o)(20) of this chapter.
( 2 ) The ingredient is used in foods at levels not to exceed current good manufacturing practice. The ingredient may also be used in infant formula in accordance with section 412(g) of the Federal Food, Drug, and Cosmetic Act (the Act) or with regulations promulgated under section 412(a)(2) of the Act.
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[48 FR 51148, Nov. 7, 1983]
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 03-6163

DE’SHON PITT,

Petitioner - Appellant,

versus

DIRECTOR, DEPARTMENT OF CORRECTIONS,

Respondent - Appellee.

Appeal from the United States District Court for the Eastern

District of Virginia, at Alexandria. T.S. Ellis, III, District

Judge. (CA-02-1879-AM)

Submitted: July 10, 2003 Decided: July 15, 2003

Before WILKINSON, MOTZ, and TRAXLER, Circuit Judges.

Dismissed by unpublished per curiam opinion.

De’shon Pitt, Appellant Pro Se.

Unpublished opinions are not binding precedent in this circuit.

See Local Rule 36(c).
2

PER CURIAM:

De’shon Pitt, a Virginia prisoner, seeks to appeal the

district court’s order denying relief on his petition filed under

28 U.S.C. § 2254 (2000). An appeal may not be taken from the final

order in a § 2254 proceeding unless a circuit justice or judge

issues a certificate of appealability. 28 U.S.C. § 2253(c)(1)

(2000). A certificate of appealability will not issue absent “a

substantial showing of the denial of a constitutional right.” 28

U.S.C. § 2253(c)(2) (2000). A prisoner satisfies this standard by

demonstrating that reasonable jurists would find that his

constitutional claims are debatable and that any dispositive

procedural rulings by the district court are also debatable or

wrong. See Miller-El v. Cockrell, 123 S. Ct. 1029, 1040 (2003);

Slack v. McDaniel, 529 U.S. 473, 484 (2000); Rose v. Lee, 252 F.3d

676, 683 (4th Cir.), cert. denied, 534 U.S. 941 (2001). We have

independently reviewed the record and conclude that Pitt has not

made the requisite showing. Accordingly, we deny Pitt’s motion for

a certificate of appealability and dismiss the appeal. We dispense

with oral argument because the facts and legal contentions are

adequately presented in the materials before the court and argument

would not aid the decisional process. 

DISMISSED
#### People of the State of Illinois, Plaintiff-Appellee, v. Edwin Dixon (Impleaded), Defendant-Appellant.

Gen. No. 52,824. (Abstract of Decision.)

First District, Second Division.

June 10,1969.

Gerald W. Getty, Public Defender of Cook County, of Chicago (John E. Hughes, Shelvin Singer, and James J. Doherty, Assistant Public Defenders, of counsel), for appellant; Edward V. Hanrahan, State’s Attorney of Cook County, of Chicago (Elmer C. Kissane and James B. Haddad, Assistant State’s Attorneys, of counsel), for appellee.

Opinion by JUSTICE McCORMICK. Not to be published in full.
<PAGE>   1
                                  EXHIBIT 24.2

                                POWER OF ATTORNEY
                                ROBERT T. KNIGHT

     KNOW ALL MEN BY THESE PRESENTS, that the undersigned, Robert T. Knight,
hereby constitutes and appoints Gordon A. Gardiner or Peter A. Allen his true
and lawful attorney-in-fact and agent, for him and his name, place and stead, in
any and all capacities, to sign the Form 10-K of Data Dimensions, Inc., a
Delaware corporation, for the fiscal year ended December 31, 1998, and any
amendments or supplements thereto, and to file this Power of Attorney and the
Form 10-K, with all exhibits thereto, and other documents in connection
therewith, with the Securities and Exchange Commission and the NASDAQ National
Market System, granting unto said attorney-in-fact and agent full power and
authority to do and perform each requisite and necessary to be done in and about
the premises, as fully to all intents and purposes as he might or could do in
person, hereby ratifying and confirming all that said attorney-in-fact and
agent, may do or cause to be done by virtue hereof.


     Dated this 4th day of March, 1999.


Signature:


/s/  ROBERT T. KNIGHT
-------------------------
Robert T. Knight
#### § 20.115 Product codes for manufacturing or sales dates.

Data or information in Food and Drug Administration files which provide a means for deciphering or decoding a manufacturing date or sales date or use date contained on the label or in labeling or otherwise used in connection with a product subject to the jurisdiction of the Food and Drug Administration are available for public disclosure.
EXHIBIT 32.2


CERTIFICATION PURSUANT TO
 PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)


In connection with the Quarterly Report on Form 10-Q of Southwall Technologies Inc. (the “Company”), for the quarter ended March 31, 2011, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mallorie Burak, the Principal Financial Officer of the Company, hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) that:





1)
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and2)
the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.











Date:    May 12, 2011
By:
/s/ Mallorie BurakMallorie BurakVice President and Chief Accounting Officer





A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Defense

###### Office of the Secretary

# AGENCY:

National Defense University, DoD.

# ACTION:

Notice of open meeting.

# SUMMARY:

The National Defense University, Designated Federal Officer, has scheduled a meeting of the Board of Visitors (BOV). The BOV is a Federal Advisory Board that meets twice a year in proceedings that are open to the public.

# DATES:

The meeting will be held on April 15 (from 11:30 a.m. to 5 p.m.) and on April 16 (from 8 a.m. to 12:30 p.m.), 2010.

# ADDRESSES:

The meeting will be held at: Marshall Hall, Building 62, Room 155, the National Defense University, 300 5th Avenue, SW., Fort McNair, Washington, DC 20319-5066.

# FOR FURTHER INFORMATION CONTACT:

Ms. Dolores Hodge by phone (202) 685-2649, fax (202) 685-7707 or e-mail HodgeD@ndu.edu.

# SUPPLEMENTARY INFORMATION:

                    The future agenda will include discussion on Defense transformation, faculty development, facilities, information technology, curriculum development, post 9/11 initiatives as well as other operational issues and areas of interest affecting the day-to-day operations of the National Defense University and its components. The meeting is open to the public; limited space made available for observers will be allocated on a first come, first served basis. Written statements to the committee may be submitted at any time or in response to a stated planned meeting agenda by fax or e-mail (                    *see***FOR FURTHER INFORMATION CONTACT**                    ). The subject line of the e-mail should read: “Comment/Statement to the NDU BOV.”                

Dated: January 7, 2010.

Mitchell S. Bryman,

Alternate OSD Federal Register Liaison Officer, Department of Defense.

[FR Doc. 2010-395 Filed 1-12-10; 8:45 am]

BILLING CODE 5001-06-P
<PAGE>   1
                          [ARTHUR ANDERSEN LETTERHEAD]


September 4, 1998




Securities and Exchange Commission
Mail Stop 9-5
450 Fifth Street, N.W.
Washington, D.C. 20549


We have read Item 4 included in the attached Form 8-K dated April 8, 1998 of
Automotive Performance Group, Inc. to be filed with the Securities and Exchange
Commission and are in agreement with the statements contained therein.


Very truly yours,


/s/ ARTHUR ANDERSEN LLP
-----------------------
# Fourth Court of Appeals **San Antonio, Texas**
April 13, 2022

No. 04

- 22

- 00013

- CV
THE HENDERSON

- WESSENDORFF FOUNDATION , Appellant

v. PIONEER NATURAL RESOURCES USA, INC., Appellee
From the 218th Judicial District Court , Karnes County, Texas Trial Court No. 17

- 08

- 00196

- CVK Honorable Lynn Ellison , Judge Presiding



### ORDER Appe llant’ s brief was originally due March 24 , 202 2

. We granted a ppellant’s first motion for extension of time , extending the deadline for filing the brief to April 11 , 20 22 . On April 11 , 20 22 , appellant filed a motion requesting an additional extension of time to file the brief until May 1 1 , 20 22 , for a total extension of 48 days

. After consideration, we GRANT the motion and ORDER appellant to file the brief by May 1 1 , 2022

.

_________________________________ Beth Watkins , Justice IN WITNESS WHEREOF, I have hereunto set my hand and affixed the seal of the said court on this 13th day of April, 2022

.

___________________________________ MICHAEL A. CRUZ , Clerk of Court
§ 358.350 Labeling of ingrown toenail relief drug products. ( a ) *Statement of identity.* The labeling of the product contains the established name of the product, if any, and identifies the product as an “ingrown toenail relief product” or as an “ingrown toenail discomfort reliever.”
( b ) *Indications.* The labeling of the product states, under the heading “Use,” the following: “for temporary relief of” [select one or both of the following: ‘pain’ or ‘discomfort’] “from ingrown toenails”. Other truthful and nonmisleading statements, describing only the use that has been established and listed in this paragraph (b), may also be used, as provided in § 330.1(c)(2) of this chapter, subject to the provisions of section 502 of the Federal Food, Drug, and Cosmetic Act (the act) relating to misbranding and the prohibition in section 301(d) of the act against the introduction or delivery for introduction into interstate commerce of unapproved new drugs in violation of section 505(a) of the act.
( c ) *Warnings.* The labeling of the product contains the following warnings under the heading “Warnings”: ( 1 ) “For external use only” in accord with § 201.66(c)(5)(i) of this chapter.
( 2 ) “Do not use [bullet][1] on open sores”.
( 3 ) “Ask a doctor before use if you have [bullet] diabetes [bullet] poor circulation [bullet] gout”.
( 4 ) “When using this product [bullet] use with a retainer ring”.
( 5 ) “Stop use and ask a doctor if [bullet] redness or swelling of your toe increases [bullet] discharge is present around the nail [bullet] symptoms last more than 7 days or clear up and occur again within a few days”.
( d ) *Directions.* The labeling of the product contains the following statements under the heading “Directions”: ( 1 ) “[Bullet] adults and children 12 years and over:” ( i ) “[Bullet] wash the affected area and dry thoroughly [bullet] place retainer ring on toe with slot over the area where the ingrown nail and the skin meet. Smooth ring down firmly. [bullet] apply enough gel product to fill the slot in the ring [bullet] place round center section of bandage strip directly over the gel-filled ring to seal the gel in place. Smooth ends of bandage strip around toes.”
( ii ) “[Bullet] repeat twice daily (morning and night) for up to 7 days until discomfort is relieved or until the nail can be lifted out of the nail groove and easily trimmed”.
( 2 ) “[Bullet] children under 12 years: ask a doctor”.
Footnotes -
358.350
[1] See § 201.66(b)(4) of this chapter for definition of bullet.
118TH CONGRESS 

2D SESSION H. R. 7158 

AN ACT 

To designate the facility of the United States Postal Service 

located at 201 East Battles Road in Santa Maria, California, as the ‘‘Larry Lavagnino Post Office Building’’. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 
2 

•HR 7158 EH

1 SECTION 1. LARRY LAVAGNINO POST OFFICE BUILDING. 

2 (a) DESIGNATION.—The facility of the United States 

3 Postal Service located at 201 East Battles Road in Santa 

4 Maria, California, shall be known and designated as the 

5 ‘‘Larry Lavagnino Post Office Building’’. 

6 (b) REFERENCES.—Any reference in a law, map, reg7 ulation, document, paper, or other record of the United 

8 States to the facility referred to in subsection (a) shall 

9 be deemed to be a reference to the ‘‘Larry Lavagnino Post 

10 Office Building’’. 

Passed the House of Representatives December 4, 

2024. 

Attest: 

Clerk. 

118TH CONGRESS 

2D SESSION H. R. 7158 

AN ACT 

To designate the facility of the United States PostLavagnino Post Office Building’’. Santa Maria, California, as the ‘‘Larry al Service located at 201 East Battles Road in